Tim Watts, CFO at Shield Therapeutics #STX presenting at our Life Sciences Investor Briefing Watch Now

Pin to quick picksErgomed Regulatory News (ERGO)

Share Price Information for Ergomed (ERGO)

London Stock Exchange
Share Price: 288.00
Bid: 286.00
Ask: 290.00
Change: -3.00 (-1.03%)
Spread: 4.00 (1.40%)
Open: 291.00
High: 291.00
Low: 288.00
Yest. Close: 291.00
ERGO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Ergomed plc - Notice of Interim Results

Thu, 29th Aug 2019 07:00

RNS Number : 4736K
Ergomed plc
29 August 2019
 

 

PRESS RELEASE

 

Notice of Interim Results

 

 

Guildford, UK - 29 August 2019: Ergomed plc, (LSE: ERGO) ("Ergomed" or the "Company"), a company focused on providing specialised services to the pharmaceutical industry, will announce its interim results for the six months ending 30 June 2019 on 25 September 2019.

 

Miroslav Reljanovic, Executive Chairman and Richard Barfield, Chief Financial Officer will host a presentation and conference call for analysts at 11am BST on the day of the results at the offices of Numis, 10 Paternoster Sq., London EC4M 7LT.

 

ENDS

 

Enquiries:

 

Ergomed plc

 Tel: +44 (0) 1483 402 975

Miroslav Reljanovic (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Numis Securities Limited

Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Huw Jeremy (Nominated Adviser)

James Black (Broker)

Consilium Strategic Communications - for UK enquiries

Tel: +44 (0) 20 3709 5700

Chris Gardner / Sue Stuart

ergomed@consilium-comms.com

Matthew Neal / Olivia Manser

MC Services - for Continental European enquiries

Tel: +49 211 5292 5222

Anne Hennecke

 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognised specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NORBLGDIRXDBGCI
Date   Source Headline
18th Sep 20197:00 amRNSErgomed plc - Board Change
2nd Sep 20197:00 amRNSErgomed plc - Total Voting Rights
29th Aug 20197:00 amRNSErgomed plc - Notice of Interim Results
20th Aug 20197:00 amRNSErgomed plc - Board Appointment
1st Aug 20197:00 amRNSErgomed plc - Total Voting Rights

Login to your account

Don't have an account? Click here to register.